Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Mar;36(3):632–638. doi: 10.1128/aac.36.3.632

Fleroxacin pharmacokinetics in patients with liver cirrhosis.

R A Blouin 1, B A Hamelin 1, D A Smith 1, T S Foster 1, W J John 1, H A Welker 1
PMCID: PMC190569  PMID: 1622175

Abstract

In this open-label study, the disposition of fleroxacin in liver disease in 12 healthy male volunteers, 6 male cirrhotics without ascites (group A), and 6 male cirrhotics with ascites (group B) was evaluated. Fleroxacin (400 mg) was administered orally and intravenously to each subject in a random crossover fashion. Fleroxacin was completely absorbed and achieved similar peak concentrations in plasma in all three study groups (P greater than 0.05). The volume of distribution exceeded 1 liter/kg in healthy controls and was not affected by liver impairment (P greater than 0.05). Only group B demonstrated differences in the pharmacokinetic parameters evaluated: the systemic and renal clearances of fleroxacin and the renal clearances and clearances of the two major metabolites of fleroxacin formed, N-demethyl fleroxacin and fleroxacin N-oxide, were significantly lower and the half-lives of the parent drug and its metabolites were significantly longer in group B than in healthy controls and group A (P less than 0.05). The elimination of the two metabolites appeared to be formation rate limited in all three study groups. It was concluded from this study that a 50% reduction in the fleroxacin maintenance dose in patients with liver disease appears justified only in patients with ascites. However, no change in the fleroxacin loading dose is needed in patients with compromised liver function.

Full text

PDF
632

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aoyama H., Inoue M., Mitsuhashi S. In-vitro and in-vivo antibacterial activity of fleroxacin, a new fluorinated quinolone. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):99–114. doi: 10.1093/jac/22.supplement_d.99. [DOI] [PubMed] [Google Scholar]
  2. Bremner D. A., Dickie A. S., Singh K. P. In-vitro activity of fleroxacin compared with three other quinolones. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):19–23. doi: 10.1093/jac/22.supplement_d.19. [DOI] [PubMed] [Google Scholar]
  3. Chang S. L., Emmick K., Wedlund P. J. Characterization of antipyrine autoinduction in the rat utilizing a new microsampling technique for serial blood sample collections. J Pharm Sci. 1986 May;75(5):456–458. doi: 10.1002/jps.2600750507. [DOI] [PubMed] [Google Scholar]
  4. Chin N. X., Brittain D. C., Neu H. C. In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone. Antimicrob Agents Chemother. 1986 Apr;29(4):675–680. doi: 10.1128/aac.29.4.675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Conn H. O. A peek at the Child-Turcotte classification. Hepatology. 1981 Nov-Dec;1(6):673–676. doi: 10.1002/hep.1840010617. [DOI] [PubMed] [Google Scholar]
  6. De Lepeleire I., Van Hecken A., Verbesselt R., Tjandra-Maga T. B., De Schepper P. J. Comparative oral pharmacokinetics of fleroxacin and pefloxacin. J Antimicrob Chemother. 1988 Aug;22(2):197–202. doi: 10.1093/jac/22.2.197. [DOI] [PubMed] [Google Scholar]
  7. Griggs D. J., Wise R., Kirkpatrick B., Ashby J. P. The metabolism and pharmacokinetics of fleroxacin in healthy subjects. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):191–194. doi: 10.1093/jac/22.supplement_d.191. [DOI] [PubMed] [Google Scholar]
  8. Manek N., Andrews J. M., Wise R. In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents. Antimicrob Agents Chemother. 1986 Aug;30(2):330–332. doi: 10.1128/aac.30.2.330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. McManus M. E., Stupans I., Burgess W., Koenig J. A., Hall P. M., Birkett D. J. Flavin-containing monooxygenase activity in human liver microsomes. Drug Metab Dispos. 1987 Mar-Apr;15(2):256–261. [PubMed] [Google Scholar]
  10. Nakashima M., Kanamaru M., Uematsu T., Takiguchi A., Mizuno A., Itaya T., Kawahara F., Ooie T., Saito S., Uchida H. Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):133–144. doi: 10.1093/jac/22.supplement_d.133. [DOI] [PubMed] [Google Scholar]
  11. Paganoni R., Herzog C., Braunsteiner A., Hohl P. Fleroxacin: in-vitro activity worldwide against 20,807 clinical isolates and comparison to ciprofloxacin and norfloxacin. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):3–17. doi: 10.1093/jac/22.supplement_d.3. [DOI] [PubMed] [Google Scholar]
  12. Riggs D. S., Guarnieri J. A., Addelman S. Fitting straight lines when both variables are subject to error. Life Sci. 1978 Apr 3;22(13-15):1305–1360. doi: 10.1016/0024-3205(78)90098-x. [DOI] [PubMed] [Google Scholar]
  13. Singlas E., Leroy A., Sultan E., Godin M., Moulin B., Taburet A. M., Dhib M., Fillastre J. P. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis. Clin Pharmacokinet. 1990 Jul;19(1):67–79. doi: 10.2165/00003088-199019010-00005. [DOI] [PubMed] [Google Scholar]
  14. Sorgel F., Metz R., Naber K., Seelmann R., Muth P. Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):155–167. doi: 10.1093/jac/22.supplement_d.155. [DOI] [PubMed] [Google Scholar]
  15. Sörgel F., Jaehde U., Naber K., Stephan U. Pharmacokinetic disposition of quinolones in human body fluids and tissues. Clin Pharmacokinet. 1989;16 (Suppl 1):5–24. doi: 10.2165/00003088-198900161-00004. [DOI] [PubMed] [Google Scholar]
  16. Sörgel F., Seelmann R., Naber K., Metz R., Muth P. Metabolism of fleroxacin in man. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):169–178. doi: 10.1093/jac/22.supplement_d.169. [DOI] [PubMed] [Google Scholar]
  17. Teunissen M. W., Meerburg-van der Torren J. E., Vermeulen N. P., Breimer D. D. Automated high-performance liquid chromatographic determination of antipyrine and its main metabolites in plasma, saliva and urine, including 4,4'-dihydroxyantipyrine. J Chromatogr. 1983 Dec 9;278(2):367–378. [PubMed] [Google Scholar]
  18. Weidekamm E., Portmann R., Partos C., Dell D. Single and multiple dose pharmacokinetics of fleroxacin. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):145–154. doi: 10.1093/jac/22.supplement_d.145. [DOI] [PubMed] [Google Scholar]
  19. Weidekamm E., Portmann R., Suter K., Partos C., Dell D., Lücker P. W. Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. Antimicrob Agents Chemother. 1987 Dec;31(12):1909–1914. doi: 10.1128/aac.31.12.1909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Wise R., Honeybourne D., Andrews J. M., Ashby J. P. The penetration of fleroxacin into bronchial mucosa. J Antimicrob Chemother. 1988 Aug;22(2):203–206. doi: 10.1093/jac/22.2.203. [DOI] [PubMed] [Google Scholar]
  21. Wise R., Kirkpatrick B., Ashby J., Griggs D. J. Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone. Antimicrob Agents Chemother. 1987 Feb;31(2):161–163. doi: 10.1128/aac.31.2.161. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES